Drug intelligence / Profile preview

G4-1

Development stage: Preclinical
Lead developer: University of Kentucky
Modality: Small Molecules

Overview

G4-1 is a non-peptide small molecule proteasome inhibitor under investigation for the treatment of solid tumors. Unlike current proteasome inhibitors, which are peptides and have low in vivo stability, G4-1 is designed to display high in vivo stability, making it a promising candidate for cancer therapy. Preclinical data showed promising anti-tumor activity and a survival study in mice is being conducted to determine its potential benefit over existing marketed drugs for solid tumors.

Targets

PSMB5 (Proteasome subunit beta Type-5)PSMB8 (Immunoproteasome)

Beyond the preview

Go deeper on G4-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G4-1.

Explore the full profile